Immunocore Holdings plc Finance Costs
Immunocore Holdings plc (IMCR) reported Finance Costs of GBP 1.56 million for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:FinanceCosts · last filed 2023-08-10
- Immunocore Holdings plc finance costs for the quarter ending 2023-06-30 was 1.56M GBP, a 12.03% increase year-over-year.
- Immunocore Holdings plc finance costs for the quarter ending 2022-12-31 was 3.18M GBP, a 135.68% increase year-over-year.
- Immunocore Holdings plc finance costs for the quarter ending 2022-09-30 was 1.78M GBP, a 35.54% increase year-over-year.
- Immunocore Holdings plc finance costs for the quarter ending 2022-06-30 was 1.40M GBP.
| Period end | Finance Costs 3 month | Finance Costs 6 month | Finance Costs 9 month | Finance Costs 12 month |
|---|---|---|---|---|
| 2023-06-30 | 1.56M GBP 6-K · filed 2023-08-10 | 3.19M GBP 6-K · filed 2023-08-10 | ||
| 2022-12-31 | 3.18M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 4.96M GBP derived: sum of 2 quarters · filed 2023-03-01 | 6.36M GBP derived: sum of 3 quarters · filed 2023-08-10 | 7.69M GBP 20-F · filed 2023-03-01 |
| 2022-09-30 | 1.78M GBP 6-K/A · filed 2022-11-18 | 3.18M GBP derived: sum of 2 quarters · filed 2023-08-10 | 4.51M GBP 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | 1.40M GBP 6-K · filed 2023-08-10 | 2.73M GBP 6-K · filed 2023-08-10 | ||
| 2021-12-31 | 1.35M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 2.67M GBP derived: sum of 2 quarters · filed 2023-03-01 | 5.81M GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | 1.32M GBP 6-K/A · filed 2022-11-18 | 4.46M GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | 3.38M GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | 9.38M GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | 842.00K GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |